Related Experiment Video
Updated: Oct 16, 2025
14:56
Sample Preparation to Bioinformatics Analysis of DNA Methylation: Association Strategy for Obesity and Related Trait Studies
Published on: May 6, 2022
4.7K
IL-6 Polymorphisms Are Not Related to Obesity Parameters in Physically Active Young Men
Ewelina Maculewicz1,2, Bożena Antkowiak2, Oktawiusz Antkowiak2
1Faculty of Physical Education, Jozef Pilsudski University of Physical Education in Warsaw, 00-809 Warsaw, Poland.
Genes
|October 23, 2021
Summary
This study found no link between Interleukin 6 (IL-6) gene variations and obesity in young, active men. Lifestyle factors may outweigh genetic predisposition in low-grade obesity.
Area of Science:
- Immunology
- Metabolic research
- Genetics
Background:
- Interleukin 6 (IL-6) acts as a cytokine and metabolic hormone, influencing immune responses and metabolism.
- IL-6's role in obesity is debated, with conflicting research findings.
- Environmental factors can confound studies on IL-6 and obesity.
Purpose of the Study:
- To investigate the association between specific Interleukin 6 (IL-6) Single Nucleotide Polymorphisms (SNPs) and obesity parameters.
- To minimize confounding factors by studying a homogenous population of young, physically active males.
Main Methods:
- Analysis of IL-6 SNPs (rs1800795, rs1800796, rs13306435) in a homogenous group of young, male military professionals.
- Subjects were categorized based on Body Mass Index (BMI) and body fat percentage (fat%).
Main Results:
- No significant association was found between the analyzed IL-6 polymorphisms (rs1800795, rs1800796, rs13306435) and obesity parameters (BMI, fat%).
Conclusions:
- Genetic predisposition related to IL-6 may have a minor effect in low-grade obesity.
- Lifestyle modifications might mitigate or overcome the impact of IL-6 genetic factors on obesity.
Related Concept Videos
01:24Obesity
716
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
716
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
21
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
21
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
19
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
19
01:21Drug Dosing: Obese Patients
16
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
16